B8F.DE - Biofrontera AG

XETRA - XETRA Delayed Price. Currency in EUR
6.50
+0.01 (+0.15%)
As of 10:13AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close6.49
Open6.49
Bid6.45 x 84600
Ask6.48 x 20000
Day's Range6.47 - 6.49
52 Week Range4.78 - 6.58
Volume2,604
Avg. Volume36,515
Market Cap289.882M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateApr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.94
  • GlobeNewswire10 days ago

    Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports positive results for the secondary endpoints of its Phase III clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz® in combination with the BF-RhodoLED® lamp for the treatment of actinic keratoses (AK) on the extremities or trunk/neck. In line with the result for the primary endpoint of the study (see ad hoc report dated March 20, 2019), which showed a mean lesion clearance rate per patient’s side of 86% for Ameluz® compared to 33% for placebo, significant superiority of Ameluz® was demonstrated for all secondary parameters investigated. In patients treated on the extremities, mean lesion clearance rates per patient’s side were also 84% with Ameluz® compared to 27% with placebo.

  • GlobeNewswire10 days ago

    Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

    Leverkusen, Germany, April 16, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.

  • GlobeNewswire11 days ago

    Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2019. The preliminary unaudited revenue of the Company for the period January to March 2019 was around EUR 6.8 million. This represents a revenue growth of approximately 46% compared to the previous year period, with pure product sales increasing by around 48%.

  • GlobeNewswire24 days ago

    Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH

    Leverkusen, Germany, April 02, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about.

  • GlobeNewswirelast month

    Changes in the composition of the Supervisory Board

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Local District Court (Amtsgericht) dismissed Mr. Hansjörg Plaggemars as a member of the Supervisory Board of Biofrontera AG in accordance with § 103 (3) AktG for cause. In January 2019, the Supervisory Board of Biofrontera AG filed an application with the Cologne Local Court to dismiss Mr. Plaggemars.

  • GlobeNewswirelast month

    Biofrontera provides corporate update; conference call details for March 26, 2019

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a conference call to be held tomorrow to provide a detailed corporate update on its acquisition of Cutanea Life Sciences, Inc. (“Cutanea”). As announced earlier today, Biofrontera acquired 100% of the stock of Cutanea, a specialty pharmaceutical company focused on dermatology products from Maruho Co., Ltd. (“Maruho”). This transaction is expected to strengthen Biofrontera’s U.S. market presence and allow it to compete more effectively in the U.S. dermatology market by adding Cutanea’s products and expertise to its existing core business.

  • GlobeNewswirelast month

    Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA

    Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA (“Cutanea”) through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan (“Maruho”) as the seller. Cutanea is a US-based pharmaceutical company specializing in dermatology.

  • GlobeNewswirelast month

    Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

    Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical.

  • GlobeNewswirelast month

    Biofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz®

    Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to continue the expired research cooperation with Maruho Co., Ltd., Osaka, Japan (“Maruho”) regarding branded generics. As part of the newly agreed project phase Biofrontera will prepare the formulation of one of the four active ingredients in Biofrontera’s nanoemulsion jointly tested during a previous project phase (Phase 1) for clinical trials.

  • GlobeNewswire2 months ago

    Biofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year

    Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that its wholly owned US-subsidiary Biofrontera Inc. earned a Silver Stevie Award for outstanding Customer Service Department of the Year - Healthcare, Pharmaceuticals, and Related Industries. The Stevie Awards for Sales & Customer Service are the world's top honors for customer service, contact center, business development, and sales professionals.